AI Article Synopsis
- This study assessed the prognostic value of INTERMACS profiles in non-inotrope-dependent heart failure patients with reduced ejection fraction (HFrEF), finding limited existing data on this topic.
- The research analyzed 3-year outcomes for 969 outpatients, categorizing them into various INTERMACS profiles based on their baseline conditions, revealing significant differences in mortality and hospitalization rates.
- Results indicated that patients classified with lower INTERMACS profiles had much higher mortality and hospitalization risks compared to stable Stage C patients, highlighting the effectiveness of these profiles for predicting outcomes in this patient group.
Article Abstract
Objectives: This study sought to evaluate INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support) profiles for prognostic use among ambulatory non-inotrope-dependent patients with heart failure with reduced ejection fraction (HFrEF).
Background: Data for INTERMACS profiles and prognoses in ambulatory patients with HFrEF are limited.
Methods: We evaluated 3-year outcomes in 969 non-inotrope-dependent outpatients with HFrEF (EF: ≤40%) not previously receiving advanced HF therapies. Patients meeting an INTERMACS profile at baseline were classified as profile 7 (n = 348 [34.7%]); 146 patients (14.5%) were classified profile 6; and 52 patients (5.2%) were classified profile 4 to 5. Remaining patients were classified "stable Stage C" (n = 423 [42.1%]).
Results: Three-year mortality rate was 10.0% among stable Stage C patients compared with 21.8% among INTERMACS profile 7 (hazard ratio [HR] vs. Stage C: 2.45; 95% confidence interval [CI]: 1.64 to 3.66), 26.0% among profile 6 (HR: 3.93; 95% CI: 1.64 to 3.66), and 43.8% among profile 4 to 5 (HR: 6.35; 95% CI: 3.51 to 11.5) patients. Hospitalization rates for HF were 4-fold higher among INTERMACS profile 7 (38 per 100 patient-years; rate ratio [RR] vs. Stage C: 3.88; 95% CI: 2.70 to 5.35), 6-fold higher among profile 6 patients (54 per 100 patient-years; RR: 5.69; 95% CI: 3.72 to 8.71), and 10-fold higher among profile 4 to 5 patients (69 per 100 patient-years; RR: 9.96; 95% CI: 5.15 to 19.3) than stable Stage C patients (11 per 100 patient-years). All-cause hospitalization rates had similar trends. INTERMACS profiles offered better prognostic separation than NYHA functional classifications.
Conclusions: INTERMACS profiles strongly predict subsequent mortality and hospitalization burden in non-inotrope-dependent outpatients with HFrEF. These simple profiles could therefore facilitate and promote advanced HF awareness among clinicians and planning for advanced HF therapies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jchf.2018.03.018 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Over 100 Fontan Patients on Systemic Ventricular Assist Device Support: An ACTION Update.
ASAIO J
December 2024
Department of Pediatrics, Children's Hospital of Colorado, Aurora, Colorado.
As the Fontan population grows, understanding successful strategies for ventricular assist device (VAD) support of the failing Fontan circulation is needed. We performed a retrospective analysis of patients with Fontan circulation and systemic VAD support in the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) registry. Competing outcomes and Kaplan-Meier estimated survival methods were used.
View Article and Find Full Text PDFSurvival of a patient following initial left ventricular assist device implantation and two successive left ventricular assist device exchanges: case report.
Eur Heart J Case Rep
December 2024
Department of Anesthesiology, Center for Clinical and Translational Research, Helios University Hospital Wuppertal, Heusnerstraße 40, 42283 Wuppertal, Germany.
Background: Initially conceptualized as a bridge to heart transplantation, the left ventricular assist device (LVAD) has become an important option for improving survival in patients with severe heart failure and poor prognosis.
Case Summary: We report the case of a patient suffering from severe chronic heart failure, complicated by ST-elevation myocardial infarction due to left main coronary artery stenosis (NYHA IV, INTERMACS profile 1). Despite support with veno-arterial extracorporeal membrane oxygenation, inotropes, and catecholamine therapy, the patient's cardiac function did not recover sufficiently.
Mitral Transcatheter Edge-to-Edge Repair in INTERMACS 3-4 Profile Patients with Severe Mitral Regurgitation.
J Cardiovasc Dev Dis
November 2024
Cardiovascular and Thoracic Department, Division of Cardiology, Città della Salute e della Scienza Hospital, 10126 Turin, Italy.
Background: Heart transplantation and left ventricular assist device (LVAD) implementation are effective treatments for advanced heart failure (HF), although their use is limited by organ availability and the high incidence of adverse events. The efficacy of mitral transcatheter edge-to-edge repair (TEER) as a bridge to transplantation or as a destination therapy in advanced HF is still debated.
Methods: A total of 63 patients with INTERMACS class 3 or 4 with contraindications for LVAD and severe functional mitral regurgitation (FMR) were evaluated for TEER implantation eligibility.
A Machine Learning-derived Risk Score Improves Prediction of Outcomes After LVAD Implantation: An Analysis of the INTERMACS Database.
J Card Fail
October 2024
Cardiology Department, University of California San Diego, La Jolla, California.
Background: Significant variability in outcomes after left ventricular assist device (LVAD) implantation emphasize the importance of accurately assessing patients' risk before surgery. This study assesses the Machine Learning Assessment of Risk and Early Mortality in Heart Failure (MARKER-HF) mortality risk model, a machine learning-based tool using 8 clinical variables, to predict post-LVAD implantation mortality and its prognostic enhancement over the Interagency Registry of Mechanically Assisted Circulatory Support (INTERMACS) profile.
Methods: Analyzing 25,365 INTERMACS database patients (mean age 56.
Different ECLS Pump Configurations for Temporary Right Ventricular Assist Device in LVAD Patients: A Retrospective Case-Control Study.
Life (Basel)
October 2024
Clinic for Thoracic and Cardiovascular Surgery, Heart and Diabetes Centre North Rhine Westphalia, 32545 Bad Oeynhausen, Germany.
Background: Acute right ventricular failure is a critical complication after left ventricular assist device (LVAD) implantation, often managed with a temporary paracorporeal right ventricular assist device (RVAD). This study examined three extracorporeal life support (ECLS) systems regarding mortality, bleeding complications, and intensive care unit (ICU) stay duration.
Methods: This monocentric, retrospective case-control study included all patients receiving LVAD with paracorporeal RVAD between 2009 and 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!